###begin article-title 0
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies. Breast cancer 1 gene (BRCA1)-deficient tumors are usually of the basal subtype and associated with poor survival rates, highlighting the need for more effective therapy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
We investigated a mouse model that closely mimics breast cancer arising in BRCA1-mutation carriers to better understand the molecular mechanism of tumor progression and tested whether targeting of the Polycomb-group protein EZH2 would be a putative therapy for BRCA1-deficient tumors.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Gene expression analysis demonstrated that EZH2 is overexpressed in BRCA1-deficient mouse mammary tumors. By immunohistochemistry we show that an increase in EZH2 protein levels is also evident in tumors from BRCA1-mutation carriers. EZH2 is responsible for repression of genes driving differentiation and could thus be involved in the undifferentiated phenotype of these tumors. Importantly, we show that BRCA1-deficient cancer cells are selectively dependent on their elevated EZH2 levels. In addition, a chemical inhibitor of EZH2, 3-deazaneplanocin A (DZNep), is about 20-fold more effective in killing BRCA1-deficient cells compared to BRCA1-proficient mammary tumor cells.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
We demonstrate by specific knock-down experiments that EZH2 overexpression is functionally relevant in BRCA1-deficient breast cancer cells. The effectiveness of a small molecule inhibitor indicates that EZH2 is a druggable target. The overexpression of EZH2 in all basal-like breast cancers warrants further investigation of the potential for targeting the genetic make-up of this particular breast cancer type.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1152 1153 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Breast cancer is a heterogeneous disease. Studies by Perou and colleagues and Sorlie and colleagues have demonstrated that at least five different subtypes can be identified based on molecular profiling [1,2]. These different subtypes might arise from transformation of different cell types in the breast and/or from mutations in different genes. It has become clear that breast cancer subtypes correspond with marked differences in therapy response and overall survival, indicating that each subgroup should be treated differently [3]. To a certain extent this is already common practice, as ErbB2-overexpressing tumors are treated with herceptin and estrogen receptor (ER)-positive tumors with tamoxifen or aromatase inhibitors [4]. However, for other groups, such as the basal-type tumors that lack expression of ErbB2, ER, and progesterone receptor (PR), rationally designed treatments are currently lacking. These tumors are generally characterized by a poor differentiation grade, and it is speculated that they may arise from an undifferentiated breast epithelial cell, or at least have acquired stem cell-like properties during transformation [5]. Currently, standard treatment of these tumors is chemotherapy. Although there is an initial effect of chemotherapy agents such as anthracyclins, basal-like tumors nevertheless exhibit the worst overall survival rate of all breast cancer subtypes. This highlights the need for more effective therapies.
###end p 11
###begin p 12
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 142 147 <span type="species:ncbi:9606">women</span>
In the current study, we investigated the potential of a molecular-based therapy for a subgroup of basal-like breast tumors: those arising in women with an inherited mutation in BRCA1. These tumors are characterized by the loss of the second BRCA1 allele, concomitant loss of TP53 function and an undifferentiated, basal-like phenotype [6-9]. Consistent with their basal-like characteristics, BRCA1-deficient breast tumors exhibit aggressive behavior and are associated with poor survival. At the cellular level, an important consequence of loss of BRCA1 function is impaired DNA double-strand break repair [10]. As unresolved double-strand breaks will activate p53, resulting in either cell cycle arrest or apoptosis, there is a strong selection pressure on loss of p53 function in BRCA1-associated breast tumorigenesis. In addition, recent evidence indicates that loss of BRCA1 inhibits differentiation into ER-positive luminal cells, which might contribute to the undifferentiated phenotype [11].
###end p 12
###begin p 13
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 546 551 <span type="species:ncbi:9606">human</span>
###xml 592 597 <span type="species:ncbi:9606">human</span>
We developed a mouse model mimicking human BRCA1-deficient breast cancer to gain insight into the molecular progression of BRCA1-deficient tumors and to test putative therapies [12]. In this model, the Brca1 and p53 genes are deleted by tissue-specific expression of Cre recombinase driven by the keratin 14 promoter, which is active in basal cells of the mammary gland, including the stem cells [13]. The ensuing mammary tumors show a solid growth pattern with pushing margins, and are highly proliferative, poorly differentiated and similar to human basal-like breast cancers (ER-, PR- and human epidermal growth factor receptor (HER) 2-negative).
###end p 13
###begin p 14
###xml 93 105 93 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 114 116 114 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 112 116 112 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 178 190 178 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 190 197 190 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 201 205 201 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 648 653 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
Importantly, our mouse model allows us to compare BRCA1-deficient mammary tumors (arising in K14cre;Brca1F/F;p53F/F (KB1P) mice) with BRCA1-proficient control tumors (arising in K14cre;Brca1w.t/w.t;p53F/F (KP) mice). After comparing gene expression patterns of BRCA1-deficient mouse mammary tumors with BRCA1-proficient control tumors, we noted that Ezh2 expression was particularly high in BRCA1-deficient tumors. EZH2 is a member of the family of polycomb group proteins, which are epigenetic repressors that prevent the expression of cell cycle inhibitors and genes required for differentiation [14,15]. We and others have already observed that EZH2 overexpression is linked to aggressive tumours with a high proliferation rate and a poor prognosis [16-20].
###end p 14
###begin p 15
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
In the study presented here, we set out to determine whether increased EZH2 expression also characterizes human BRCA1-deficient breast cancer, and whether BRCA1-deficient tumor cells are dependent on high EZH2 levels for their survival. This would indicate that EZH2 constitutes a therapeutic target for BRCA1-deficient breast cancer. EZH2 is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which also contains SUZ12 and EED, and initiates gene silencing by trimethylating lysine 27 in histone H3 (H3-K27me3) [21]. Tan and colleagues recently demonstrated that a small molecule inhibitor, 3-deanzaneplanocin A (DZNep), effectively reduced the protein levels of PRC2 components EZH2, SUZ12, and EED, and inhibits the associated H3K27 trimethylation activity [22]. H3-K27me3 depletion resulted in reactivation of PRC2-silenced genes and apoptotic cell death in several cancer cell lines. The availability of a small molecule inhibitor such as DZNep allowed us to test whether pharmacological targeting of EZH2 function provides a selective approach to kill BRCA1-deficient breast tumor cells.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Derivation and maintenance of mouse tumor cell lines
###end title 17
###begin p 18
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Tumor cell lines were generated from individual tumors arising in female mice with a KB1P or KP genotype as described previously [23]. Established cell lines were cultured at 37degreesC with 5% carbondioxide in DMEM-F12 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% FCS, 50 U/ml penicillin, 50 mug/ml streptomycin (Gibco, Carlsbad, CA, USA), 5 mug/ml insulin (Sigma, St. Louis, MO, USA), 5 ng/ml epidermal growth factor (Invitrogen, Carlsbad, CA, USA) and 5 ng/ml cholera toxin (Gentaur, Brussels, Belgium).
###end p 18
###begin title 19
BRCA1 reconstitution in BRCA1-deficient tumor cells
###end title 19
###begin p 20
###xml 157 163 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 296 298 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 406 408 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 472 489 471 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 496 498 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 683 685 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 151 156 <span type="species:ncbi:9606">human</span>
###xml 235 243 <span type="species:ncbi:9606">Children</span>
###xml 472 488 <span type="species:ncbi:562">Escherichia coli</span>
###xml 670 675 <span type="species:ncbi:9606">human</span>
One million KB1P3.12 cells were electroporated (3 muF, 0.8 kV) with the bacterial artificial chromosome (BAC) clone RP11-812O5 containing the complete human BRCA1 gene and regulatory sequences. The RP11-812O5 BAC was obtained from the Children's Hospital and Research Center at Oakland, CA, USA [24]. The vector backbone was modified by insertion of the pgk/EM7 Neo/KanR-positive selection cassette pCEI1 [25] into the sacBII gene by bacterial homologous recombination in Escherichia coli SW102 [26]. After selection with 300 mug/ml Geneticin (Gibco-BRL, Carlsbad, CA, USA) for two weeks, clones were picked and checked for the presence of the BAC by PCR for exon 11 of human BRCA1 [27].
###end p 20
###begin title 21
Tumorsphere formation assay
###end title 21
###begin p 22
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Stem cell medium (SCM) containing defined growth factors as described by [28,29] was freshly prepared each time and DZNep (5 mum) or dimethyl sulfoxide (DMSO; no-drug control) was added. Cells were trypsinized, which was inactivated with 10% serum and subsequently washed with PBS to remove the serum, and resuspended in SCM. Cells were filtered to obtain single cells and 40,000 cells, counted with a Casy counter (Schaerfe Systems, Reutlingen, Germany), were plated out in ultra-low binding plates with a flat bottom (Corning Incorporated, Corning, NY, USA). Sphere formation was checked every day and cell culture images were obtained after 72 hours using a Zeiss Axiovert 25 microscope (Carl Zeiss MicroImaging, Goettingen, Germany) with 10x objective on a Sony Cybershot (Sony corporation, Tokyo, Japan).
###end p 22
###begin title 23
###xml 18 23 <span type="species:ncbi:9606">human</span>
Classification of human breast tumor samples
###end title 23
###begin p 24
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast tumor tissue samples were obtained from the pathology archive of the Netherlands Cancer Institute. BRCA1-mutation status was determined by routine DNA diagnostics. The basal-like and luminal status was determined using expression data to classify the tumors according to the intrinsic gene set as described [30].
###end p 24
###begin title 25
Immunohistochemistry
###end title 25
###begin p 26
###xml 1206 1208 1205 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 415 419 <span type="species:ncbi:9925">goat</span>
###xml 434 439 <span type="species:ncbi:10090">Mouse</span>
###xml 559 564 <span type="species:ncbi:10090">mouse</span>
Paraffin-embedded tumor samples were sectioned (4 mum) and deparaffinized by treating twice with xylene for 10 minutes each and subsequently hydrated in 100%, 80%, and 70% ethanol. Antigen retrieval was performed by boiling samples in 10 mM sodium citrate for one minute at 900 W and 15 minutes at 250 W in the microwave, followed by 20 minutes gradual cooling at room temperature. Slides were blocked in 5% normal goat serum in PBS. Mouse tissue was additionally permeabilized with 0.25% Triton prior to blocking. The samples were incubated overnight with a mouse monoclonal antibody against EZH2 (1:100, BD Biosciences San Jose, California, USA). Immunodetection was performed by diaminobenzidine (DAB) oxidation using the Powervision system (ImmunoLogic, Duiven, The Netherlands). Samples were dehydrated in 70%, 80%, and 100% ethanol. Once immunostained, slides were digitally scanned with a Scanscope (Aperio Technologies, Vista, CA, USA) and the amount of EZH2-expressing epithelial cell nuclei were counted in a blinded manner by two observers (SAJ and JP) independently. For statistical analysis, the Wilcoxon test was used to compare the percentage of EZH2-positive nuclei between two samples and P < 0.05 was considered statistically significant.
###end p 26
###begin title 27
Immunoblot analysis
###end title 27
###begin p 28
###xml 572 583 <span type="species:ncbi:3704">horseradish</span>
###xml 764 769 <span type="species:ncbi:10090">mouse</span>
###xml 888 893 <span type="species:ncbi:10090">mouse</span>
Cells were scraped from subconfluent plates and lysed in RIPA buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 1% Triton X100, 1% DOC, 0.1% SDS, 1 mM EDTA) Equal amount of protein (10 mug) was loaded and separated by electrophoresis on NuPAGE Novex 4 to 12% SDS-PAGE (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membranes. The blot was blocked with TBST (0.1% Tween 20) containing 5% BSA (Sigma-Aldrich, St. Louis, MO, USA) and incubated with primary antibodies for two hours at room temperature. After washing with TBST, the membrane was incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody and the signal was detected with enhanced chemiluminescence substrate (GE Healthcare, Amersham, UK). Following antibodies were used: mouse monoclonal against EZH2 (1:20, provided by K. Helin), beta-tubulin (1:10000, Sigma-Aldrich, St. Louis, MO, USA), anti-mouse IgG-HRP (1:10000, Biosource International, Camrillo, CA, USA).
###end p 28
###begin title 29
Quantitative real-time PCR
###end title 29
###begin p 30
###xml 565 567 555 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 578 579 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 699 704 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt </italic>
###xml 730 735 720 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt </italic>
###xml 767 772 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 799 804 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 679 684 <span type="species:ncbi:10090">mouse</span>
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and 1 mug per sample was treated with DNase. Reverse transcription was performed using the SuperScripttrade mark First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA; according to manufacturer's protocol). The generated cDNA was analyzed using SYBR Green (Taqman universal PCR master mix, Applied Biosystems, Foster City, CA, USA), performed on an ABI Prism 7000 SDS (Applied Biosystems, Foster City, CA, USA). Product accumulation was evaluated using the comparative CT method (DDCT), with Hprt levels as internal control for normalization. The following primers were used (all for mouse transcripts): Hprt FW: CTGGTGAAAAGGACCTCTCG; Hprt RV: TGAAGTACTCATTATAGTCAAGGGCA, Ezh2 FW: AAAGACCCTGAATGCAGTCGC; Ezh2 RV: TGATCCAGAACTTCATCCCCC.
###end p 30
###begin title 31
Microarray analysis
###end title 31
###begin p 32
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 461 467 461 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 356 361 <span type="species:ncbi:10090">mouse</span>
###xml 366 371 <span type="species:ncbi:9606">human</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
###xml 582 587 <span type="species:ncbi:9606">human</span>
Expression values (Log2 ratio) of Ezh2 in 21 KB1P and 32 KP mammary tumors were obtained from oligonucleotide microarrays representing 18,173 genes. Methods for RNA extraction, RNA amplification, microarray hybridization, and data processing are described by Liu and colleagues [12]. For comparison of EZH2 gene expression (Log10 ratio) signatures between mouse and human breast tumors, we used the expression profiles of 96 human breast tumors: 18 ER-negative BRCA1 tumors, 34 tumors with a good prognosis signature and 44 tumors with a poor prognosis signature categorized by the human 70-genes signature dataset [31].
###end p 32
###begin title 33
Growth inhibition assays
###end title 33
###begin p 34
###xml 994 996 981 983 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ex</sub>
###xml 1000 1003 987 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">em </sub>
###xml 1447 1449 1434 1436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
DZNep was provided by YU Qiang (Genome Institute of Singapore) and trichostatin A (TSA) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Both compounds were solved in DMSO and stored at -20degreesC. Before the growth inhibition assays, growth curves were made of all cell lines to determine the amount of cells that ensure exponential growth during a five-day culture period. For cell viability analysis, subconfluent dishes were trypsinized and filtered to obtain single cells. Cells were counted with a Casy counter and appropriate amounts of cells were typically plated out in 96-well plates on day 0. Drugs were added in twofold serial dilutions on day 1 in triplicate. DMSO was used as a no-drug control. Both drugs were left on the cells for 120 hours. On day 5 cell viability was measured using the Cell Titer Blue assay (Promega, Madison, WI, USA). Cell Titer Blue reagent was added directly to the cells (10 mul/well) and incubated for two hours at 37degreesC. Fluorescence at 560ex/590em nm was measured using a Tecan infinite m200 plate reader (Tecan, Salzburg, Austria). After correction for medium only and no-drug controls, data points were fitted to a sigmoidal dose-response curve with variable slope using GraphPad Prism Version 5.00 (GraphPad Software, San Diego, CA, USA): Y = 100/(1 + 10 ((LogIC50-X)*HillSlope))). At least three independent experiments were used to determine the half maximal inhibitory concentration (IC50) values for each drug/cell line combination.
###end p 34
###begin title 35
RNA interference and DZNep-drug treatment
###end title 35
###begin p 36
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
The SMARTpool small interfering RNA (siRNA) targeting Ezh2 and the non-targeting control were purchased from Dharmacon (Lafayette, CO, USA). Prior to all knock-down experiments optimal transfection conditions were determined for all cell lines. Cells were plated on day 0 and either transfected with 2 muM siRNA using DharmaFECT transfection reagent according to manufacturer's protocol (Dharmacon, Lafayette, CO, USA) or supplied with 5 muM DZNep on day 1. For protein and RNA analysis cells were harvested 48, 72 and 96 hours after transfection. The effect on cell growth was quantified using a Cell Titer Blue cell viability assay as described above. Cells were plated on day 0 in a density to allow exponential growth during the whole experiment and either transfected with siRNA or treated with 5 muM DZNep on day 1. Fluorescence was recorded 24, 48, 72 and 96 hours after transfection. Cell culture images were obtained using a Zeiss Axiovert 25 microscope with 10x objective on a Sony Cybershot. In all cases, data are presented from at least three independent experiments.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Ezh2 expression is elevated in BRCA1-deficient mouse mammary tumors
###end title 38
###begin p 39
###xml 169 181 169 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 190 192 190 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 188 192 188 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 288 300 288 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 300 301 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 302 303 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 300 307 300 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 311 312 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 313 315 313 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 311 315 311 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 757 762 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1305 1307 1305 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 1082 1087 <span type="species:ncbi:10090">mouse</span>
To define the molecular changes associated with BRCA1-deficient breast cancer, we previously compared BRCA1-deficient (KB1P) mammary tumors derived from our conditional K14cre;Brca1F/F;p53F/F mouse model for hereditary breast cancer with BRCA1-proficient mammary tumors (KP) derived from K14cre;Brca1w.t/w.t;p53F/F mice. Gene expression microarray analysis showed that KB1P tumors expressed markers of basal-like breast cancer, for example p63 and keratin 5, compared with the KP tumors [12,32]. Strikingly, the polycomb repressor EZH2 is also higher expressed in BRCA1-deficient tumors than in BRCA1-proficient control tumors (Figure 1a). Whereas there is heterogeneity in the BRCA1-proficient group, virtually all BRCA1-deficient tumors display increased Ezh2 expression, suggesting that in the absence of BRCA1 increased levels of EZH2 may be required. To determine whether the increase in mRNA levels translates to higher EZH2 protein expression, we analyzed tissue sections from both KB1P and KP tumors by immunohistochemistry (Figure 1b). We indeed found that BRCA1-deficient mouse mammary tumors have higher EZH2 protein levels than control tumors, also indicated by the higher percentage of tumor cells with EZH2 expression above background (77% in KB1P tumors versus 11.5% in KP tumors; Wilcoxon P < 0.029; Figure 1c).
###end p 39
###begin p 40
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 77 81 77 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 121 122 121 122 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 128 129 128 129 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 132 133 132 133 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 121 133 121 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 137 138 137 138 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 142 144 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 140 144 140 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 174 175 174 175 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 174 186 174 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;Brca1</italic>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 186 193 186 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 194 195 194 195 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 199 201 199 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 197 201 197 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 311 316 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 410 415 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 513 517 507 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 744 748 737 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Ezh2 expression is elevated in BRCA1-deficient primary mouse mammary tumors. (a) mRNA levels of Ezh2 in BRCA1-deficient (K14cre;Brca1F/F;p53F/F (KB1P)) and BRCA1-proficient (K14cre;Brca1w.t/w.t;p53F/F (KP)) mammary tumors analyzed by microarray analysis. The mean (+/- standard error of the mean) log2 ratio of Ezh2 expression in 21 KP tumors is -0.036 (+/- 0.067) and 0.497 (+/- 0.054) in 32 KB1P tumors. The Ezh2 expression is significantly higher in KB1P tumors compared with KP tumors (*Wilcoxon exact test). (b) EZH2 protein levels in two independent primary KB1P and in two independent primary KP tumors detected by immunohistochemistry (scale bar represents 100 mum), representative of a total of four tumors analysed for each genotype. (c) Quantification of EZH2 immunohistochemistry shown in b (* Wilcoxon exact test).
###end p 40
###begin title 41
###xml 41 46 <span type="species:ncbi:9606">human</span>
EZH2 is overexpressed in BRCA1-deficient human breast tumors
###end title 41
###begin p 42
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 305 308 305 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH</italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 746 751 746 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1084 1086 1084 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1169 1171 1169 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 339 344 <span type="species:ncbi:9606">human</span>
###xml 533 538 <span type="species:ncbi:9606">human</span>
Next, we determined whether EZH2 is also overexpressed in human BRCA1-deficient breast cancer. Recently, we and others showed that EZH2 levels are high in breast tumors with a poor prognosis [16,18,33]. Tumors from BRCA1-mutation carriers belong to this group of aggressive breast cancer, and accordingly EZH2 mRNA levels are also high in human BRCA1-deficient tumors (Figure 2a). Consistent with our previous observation that EZH2 mRNA and protein levels correlate relatively well [16], we observed increased EZH2 protein levels in human BRCA1-deficient tumor sections compared with other breast tumors (Figure 2b). To allow direct comparison, we simultaneously performed immunohistochemistry for EZH2 on sections from luminal A, basal-like and BRCA1-mutated breast tumors. As previously reported [16,18,33], we found EZH2 levels to be higher in basal-like tumors compared with luminal A-type tumors (Figure 2b). By the same detection criteria, EZH2 levels in the BRCA1-deficient tumors were at least as high as in the sporadic basal-like tumors (no significant difference, Wilcoxon P < 0.164) and significantly increased compared with luminal A-type tumors (Wilcoxon P < 0.002, Figure 2c).
###end p 42
###begin p 43
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 62 66 62 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 123 128 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 171 173 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 329 334 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 423 427 415 419 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 643 647 634 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 460 465 <span type="species:ncbi:9606">human</span>
EZH2 is overexpressed in BRCA1-deficient human breast tumors. (a) The mean (+/- standard error of the mean) log10 ratio of EZH2 expression in human breast cancer samples [45] is -0.15 (+/- 0.041; >five-year survival, good prognosis), 0.028 (+/- 0.046; <five-year survival, poor prognosis) and 0.177 (+/- 0.047; BRCA1-deficient). EZH2 expression is significantly different between the three groups (* Kruskall-Wallis test). (b) Immunohistochemistry for EZH2 in human breast tumor tissues (scale bar represents 100 mum). Two examples are shown of individual tumors for each subtype, representative of a total of six tumors analysed per subtype. (c) Quantification of EZH2 immunohistochemistry shown in b (* Wilcoxon exact test).
###end p 43
###begin title 44
BRCA1-deficient cells are dependent on EZH2
###end title 44
###begin p 45
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
To determine whether the increased EZH2 levels are functionally relevant in the BRCA1-deficient tumor cells, we made use of cell lines that were derived from KB1P and KP mouse mammary tumors [23]. In total, we used a panel of three BRCA1-deficient and three BRCA1-proficient cell lines, all derived from individual primary tumors. Although DZNep is a selective inhibitor of EZH2 function, some effects on other epigenetic marks, such as H4K20 methylation, have been reported [22]. To ascertain whether observed effects with DZNep are due to its inhibition of EZH2 specifically, we included siRNAs targeting Ezh2 in our experiments.
###end p 45
###begin p 46
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2</italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2</italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 959 964 959 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1275 1280 1275 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1409 1413 1409 1413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2</italic>
###xml 1717 1722 1717 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c, d</xref>
Quantitative PCR demonstrated efficient knockdown of Ezh2 mRNA levels in both BRCA1-proficient and BRCA1-deficient cells (Figure 3a). DZNep does not affect Ezh2 mRNA levels, as reported previously [22]. However, treatment with either Ezh2-specific siRNAs or DZNep resulted in significant reduction of EZH2 protein levels in both KB1P and KP cells (Figure 3b). Forty-eight hours after treatment there was visible toxicity in KB1P cells when EZH2 levels were reduced by either DZNep or siRNAs targeting Ezh2, but not in KB1P cells treated with non-targeting control siRNAs (Figure 3c). In contrast, there was no apparent effect of reduced EZH2 levels, either by Ezh2 knock-down or DZNep treatment, in BRCA1-proficient tumor cells. A more quantitative assessment of the effect of the treatments by a growth inhibition assay revealed that there is some adverse affect of DZNep in the KP cells. However, this effect of DZNep is unrelated to EZH2, as knock-down of Ezh2 does not inhibit the growth of these cells (Figure 3d, blue lines). Possibly, this is due to the effect of DZNep on H4K20 or other methylation events. In contrast, KB1P cells are severely affected by reduced EZH2 levels, as demonstrated by a strong growth inhibition of KB1P cells treated with siRNAs targeting Ezh2 (Figure 3d, red lines). In BRCA1-deficient cells, treatment with DZNep inhibited growth even more effectively than knock-down of Ezh2, which could be due to a more effective depletion of EZH2 by DZNep than that achieved by siRNAs, or due to possible effects of DZNep on other epigenetic marks. Nevertheless, DZNep shows remarkable selectivity in inhibiting BRCA1-deficient tumor cells compared with BRCA1-proficient tumor cells (Figures 3c, d).
###end p 46
###begin p 47
###xml 88 92 88 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 179 180 179 180 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 186 187 186 187 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 190 191 190 191 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 179 191 179 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 195 196 195 196 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 200 202 200 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 198 202 198 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 250 251 250 251 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 250 262 250 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;Brca1</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 262 269 262 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 270 271 270 271 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 275 277 275 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 273 277 273 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 397 401 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 404 408 403 407 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 504 509 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 622 626 620 624 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 758 763 756 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 808 812 805 809 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 940 945 937 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
EZH2 is required for survival of BRCA1-deficient but not BRCA1-proficient tumors cells. (a) Ezh2 mRNA expression measured by quantitative RT-PCR in BRCA1-deficient cells (in red, K14cre;Brca1F/F;p53F/F (KB1P)) and in BRCA1-proficient cells (in blue, K14cre;Brca1w.t/w.t;p53F/F (KP)) after treatment with siRNAs against Ezh2 or 5 muM 3-deazaneplanocin A (DZNep; shown as fold induction relative to Hprt). (b) EZH2 levels analysed by western blot after KB1P and KP cells were treated with siRNAs targeting Ezh2 or non-targeting siRNAs (siNTC) and 5 muM DZNep or vehicle (dimethyl sulfoxide (DMSO)) for the indicated period. (c) Phase-contrast images of BRCA1-deficient and BRCA1-proficient cells treated for 48 hours with control (ctrl) siRNAs, siRNAs against Ezh2 or 5 muM DZNep (original magnification 10x). (d) Growth curves of KB1P (depicted in red) and KP cell lines (depicted in blue) treated with control (ctrl) siRNAs, siRNAs against Ezh2 or 5 muM DZNep. Data measured by Cell Titer Blue and represented as the mean +/- standard error of the mean (three independent experiments). The depicted cell lines are representative for all three KB1P and KP cell lines.
###end p 47
###begin title 48
BRCA1-deficiency sensitizes cells to EZH2-inhibitor DZNep but not to TSA
###end title 48
###begin p 49
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 159 162 159 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 312 315 312 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 327 329 327 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
To better quantify the difference in sensitivity to DZNep between KB1P and KP cells, we performed a dose-response curve (Figure 4a). Strikingly, the average IC50 for BRCA1-deficient cells is 163 nM, whereas an almost 19-fold higher dose is required for 50% growth inhibition in BRCA1-proficient cells (average IC50 of 2944 nM, P < 0.0001, t-test; Table 1).
###end p 49
###begin p 50
###xml 77 81 77 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 153 154 153 154 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 160 161 160 161 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 164 165 164 165 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 153 165 153 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 165 168 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 169 170 169 170 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 174 176 174 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 172 176 172 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 226 227 226 227 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 226 238 226 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;Brca1</italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 238 245 238 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 246 247 246 247 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 251 253 251 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 249 253 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 516 520 514 518 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
Chemical EZH2-inhibitor DZNep selectively kills BRCA1-deficient tumor cells. (a) Representative growth inhibition curves for BRCA1-deficient cell lines (K14cre;Brca1F/F;p53F/F (KB1P), in blue) and BRCA1-proficient cell lines (K14cre;Brca1w.t/w.t;p53F/F (KP), in red) treated with 3-deazaneplanocin A (DZNep). A serial dilution of DZNep was added to the cells and cell viability was measured five days later (each data point represents the mean +/- standard error of the mean (SEM) of three independent experiments). (b) Representative growth inhibition curves for BRCA1-deficient cell lines (KB1P, in blue) and BRCA1-proficient cell lines (KP, in red) treated with trichostatin A (TSA). A serial dilution of TSA was added to the cells and cell viability was measured five days later (mean +/- SEM).
###end p 50
###begin p 51
###xml 2 5 2 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
IC50 values of DZNep and TSA on BRCA1-proficient vs. BRCA1-deficient mammary tumor cells
###end p 51
###begin p 52
###xml 176 178 176 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 251 252 251 252 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 251 263 251 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;Brca1</italic>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 263 270 263 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 271 272 271 272 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 276 278 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 274 278 274 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 318 321 318 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 335 336 335 336 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 342 343 342 343 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 346 347 346 347 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 335 347 335 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 347 350 347 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 351 352 351 352 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 356 358 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 354 358 354 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 387 389 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Note: Values between brackets represent the standard error of the mean (SEM) of at least three independent experiments. Ratio: Average half maximal inhibitory concentration (IC50) values of 3-deazaneplanocin A (DZNep) and trichostatin A (TSA) for the K14cre;Brca1w.t/w.t;p53F/F (KP) lines were compared with average IC50 values of the K14cre;Brca1F/F;p53F/F (KB1P) lines. *Significance: P < 0.01 (t-test).
###end p 52
###begin p 53
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 276 279 276 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 333 335 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 604 612 604 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
To exclude the possibility that KB1P cells are in general more sensitive to epigenetic inhibitors we tested the effect of the histone deacetylase-inhibitor TSA in the same growth inhibition assay (Figure 4b). TSA affected KB1P and KP cell lines to a similar extend (average IC50 of 26 nM vs 29 nM) showing no significant difference (P = 0.5; t-test, Table 1). When the cell lines were grown under non-adherent conditions, DZNep also inhibited sphere-formation, suggesting that there is no subpopulation of BRCA1-deficient cells that is resistant to DZNep treatment [see Additional data file 1]. However, in vivo experiments should demonstrate whether targeting EZH2 inhibits all tumor-initiating potential.
###end p 53
###begin title 54
Reconstitution of BRCA1 partially restores resistance to DZNep
###end title 54
###begin p 55
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 441 447 441 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 723 728 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5d</xref>
###xml 322 327 <span type="species:ncbi:9606">human</span>
As loss of BRCA1 function results in genomic instability, we wanted to establish whether the dependence on EZH2 is a direct consequence of Brca1 loss, or whether this is a secondary effect caused by mutations accumulated during the tumorigenic process. To test this, we re-introduced a BAC clone encompassing the complete human BRCA1 gene into a BRCA1-deficient cell line (KB1P-3.12) and derived several clones that were shown to re-express BRCA1 (Figure 5a). These cells became less sensitive to cisplatin treatment indicating that the introduced BRCA1 is functional (data not shown). Of note, we did not observe a decrease in EZH2 levels in the reconstituted cell lines, indicating that BRCA1 does not directly influence Ezh2 expression (Figure 5b). However, treatment with DZNep reduces EZH2 levels to a similar extent in all cell lines (Figures 3b and 5d, and data not shown).
###end p 55
###begin p 56
###xml 66 70 66 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 262 266 262 266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 302 303 302 303 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 309 310 309 310 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 313 314 313 314 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 301 314 301 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 314 317 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 318 319 318 319 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 321 322 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 323 325 323 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 321 325 321 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 343 344 343 344 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 343 355 343 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;Brca1</italic>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 357 358 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 361 362 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 355 362 355 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 363 364 363 364 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 366 370 366 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 559 563 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hprt</italic>
###xml 566 570 566 570 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 957 961 955 959 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 984 990 982 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hBRCA1</italic>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 195 200 <span type="species:ncbi:9606">human</span>
Restoration of BRCA1 partially rescues from sensitivity to DZNep. (a) Detection of the human BRCA1 allele by PCR amplification of exon 11 in the reconstituted subclones KB1PR-3.12 E3 and F4. The human breast cancer cell line T47D was used as a positive control. (b) EZH2 protein levels of (untreated) KK14cre;Brca1F/F;p53F/F (KB1P), KB1PR and K14cre;Brca1w.t/w.t;p53F/F (KP) cell lines were analysed by western blotting. Corresponding Ezh2 mRNA levels of KB1P, KB1PR and KP cell lines were measured by quantitative RT-PCR (shown as fold induction relative to Hprt). (c) Representative growth inhibition curves for BRCA1-deficient cell lines (KB1P, in blue), BRCA1-proficient cell lines (KP, in red) and two clones of a BRCA1-reconstituted cell line (KB1PR E3 and F4, in purple) treated with 3-deazaneplanocin A (DZNep). A serial dilution of DZNep was added to the cells and cell viability was measured five days later (mean +/- standard error of the mean). (d) EZH2 protein levels of hBRCA1-reconstituted KB1P cells 48 hours after treatment with DZNep or siRNAs targeting EZH2.
###end p 56
###begin p 57
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 156 159 156 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 242 245 242 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 305 308 305 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2</italic>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Interestingly, when the reconstituted cell lines were treated with DZNep, we observed a substantial rescue from DZNep-induced cell death (Figure 5c). The IC50 values for DZNep in the BRCA1-reconstituted cells lines were more similar to the IC50 values of the KP cells, than those of KB1P cells (average IC50 of 1391 nM, Table 2). This shows that sensitivity of BRCA1-deficient cells to DZNep is mainly due to a loss of BRCA1 function, and not due to secondary mutations. This also indicates that there is a synthetic lethal effect; the effect of targeting one gene (e.g. EZH2) becomes deleterious specifically in the absence of another gene (e.g. BRCA1) [34].
###end p 57
###begin p 58
###xml 2 5 2 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
IC50 values of DZNep on BRCA1-deficient vs. BRCA1-reconstituted mammary tumor cells
###end p 58
###begin p 59
###xml 176 178 176 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 226 227 226 227 <underline xmlns:xlink="http://www.w3.org/1999/xlink">K</underline>
###xml 233 234 233 234 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 237 238 237 238 <underline xmlns:xlink="http://www.w3.org/1999/xlink">1</underline>
###xml 226 238 226 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><underline>K</underline>14cre;<underline>B</underline>rca<underline>1</underline></italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 242 243 242 243 <underline xmlns:xlink="http://www.w3.org/1999/xlink">p</underline>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;<underline>p</underline>53</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 247 249 247 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F </italic>
###xml 245 249 245 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F </italic></sup>
###xml 291 294 291 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 335 337 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Note: Values between brackets represent the standard error of the mean (SEM) of at least three independent experiments. Ratio: Average half maximal inhibitory concentration (IC50) values of 3-deazaneplanocin A (DZNep) for the K14cre;Brca1F/F;p53F/F (KB1P) lines were compared with average IC50 values of the KB1P lines. *Significance: P < 0.01 (t-test).
###end p 59
###begin p 60
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 146 151 <span type="species:ncbi:10090">mouse</span>
###xml 156 161 <span type="species:ncbi:9606">human</span>
Although the reconstituted cells become over eight-times more resistant to DZNep, the rescue is not complete. This could be due to differences in mouse and human BRCA1 or to technical issues with achieving the correct amount of BRCA1 expression. Alternatively, additional mutations could play a minor role in the sensitivity to DZNep.
###end p 60
###begin p 61
In summary, we have demonstrated that DZNep selectively inhibits BRCA1-deficient but not BRCA1-proficient mammary tumor cells, and that this effect is mainly due to the fact that BRCA1-deficient cells are dependent on EZH2, whereas BRCA1-proficient cells are not.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 363 368 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 941 949 941 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1269 1274 1269 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 1364 1369 1364 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ezh2 </italic>
###xml 1494 1496 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 1471 1476 <span type="species:ncbi:10090">mouse</span>
Breast tumors in BRCA1-mutation carriers arise early in life and exhibit an aggressive, basal-like phenotype associated with poor overall survival. More insight into the molecular make-up of this breast cancer subtype will contribute to the development of more effective therapies. In this study, we demonstrate that EZH2 expression is high in breast tumors from BRCA1-mutation carriers, similar to that observed in our mouse model for BRCA1-deficient breast cancer. Moreover, the knock-down experiments show that BRCA1-deficient mammary tumor cells are dependent on EZH2 for their survival. Interestingly, although EZH2 levels were also reduced to a similar level in the BRCA1-proficient control cells, these cells seem much less affected by EZH2 loss. This indicates that targeting EZH2 is synthetic lethal in combination with BRCA1-deficiency. Conceivably, the dependence on high EZH2 levels derives from a selective advantage during the in vivo tumorigenesis process that occurs only in BRCA1-deficient and not BRCA1-proficient cells. The observation that restoration of BRCA1 does not reduce EZH2 levels suggests that the increased expression is caused by more permanent changes. However, such mutations or epigenetic alterations do not necessarily have to target Ezh2 directly, but could occur in upstream regulators of EZH2 as well. Note that selection for Ezh2 overexpression may occur in other breast tumors, as evident from some of the primary BRCA1-proficient mouse tumors in Figure 1a. The central question of this study was whether overexpression of EZH2 is required for the survival of breast tumor cells or whether this is a byproduct of the tumorigenic process, and our data suggest that whereas BRCA1-deficient cells remain dependent on their EZH2 expression, loss of EZH2 is much better tolerated in cells with intact BRCA1.
###end p 63
###begin p 64
###xml 397 407 397 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2/Ezh2 </italic>
Now that we have established the functional importance of EZH2 expression in BRCA1-deficient cells, it would be interesting to understand why these tumors are selectively dependent on EZH2, and whether this dependence is specific to loss of BRCA1 function, or more related to the basal-like characteristics of these tumors. There could be several, not mutually exclusive, reasons for selection of EZH2/Ezh2 overexpression during tumorigenesis.
###end p 64
###begin p 65
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1201 1203 1201 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1351 1353 1351 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1412 1417 1412 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
With regards to a specific role of BRCA1-deficiency, there could be an effect of EZH2 on DNA repair. It has been reported that EZH2 overexpression represses genes of the Rad51 family [35], which may attenuate DNA damage signalling in BRCA1-deficient cells. This would suggest that EZH2 overexpression could play a similar role in BRCA2-deficient tumors that are subject to the same impairment in homology-directed double-strand break repair as BRCA1-deficient tumors. However, we did not observe increased EZH2 expression in breast tumors from BRCA2-mutation carriers (data not shown), suggesting that the main oncogenic role of EZH2 is not linked to DNA repair. Another possible explanation for the selective overexpression of EZH2 in BRCA1-deficient breast tumors could involve a role of EZH2 in the cell of origin. Specifically, the absence of BRCA1 has been associated with characteristics of stem cells and loss of BRCA1 is incompatible with luminal differentiation [11]. EZH2 is required for the maintenance of embryonic and adult stem cells, is expressed in a relatively small number of cells in the mammary gland, and is only overexpressed in breast tumors with an undifferentiated phenotype [16,19,36]. In addition, a large subset of genes silenced by EZH2 includes transcription factors that orchestrate lineage-specific differentiation [37,38]. Therefore, it could be envisaged that overexpression of EZH2 is required to maintain the undifferentiated state of the transformed cell. Reducing EZH2 levels by DZNep or siRNAs might result in the expression of genes that induce differentiation, a fate potentially incompatible with the absence of BRCA1.
###end p 65
###begin p 66
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
However, overexpression of EZH2 does not seem to cause hyperrepression of typical PcG-target genes [16,39], suggesting that it has consequences distinct from silencing its normal target genes. Several groups have indeed found evidence for genes marked by PcG proteins specifically in tumor cells [22,40]. It remains to be established, however, whether silencing of these genes is responsible for the selective advantage of EZH2 overexpression in BRCA1-deficient tumor cells, and whether these genes include more classical tumor-suppressors or specific differentiation factors.
###end p 66
###begin p 67
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 981 986 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 1301 1307 1301 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1 </italic>
###xml 1378 1383 1378 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1436 1442 1436 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1488 1494 1488 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1694 1699 1694 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 1031 1036 <span type="species:ncbi:9606">human</span>
The model for a specific function of EZH2 in more undifferentiated, basal-like cells is consistent with the observation that our KB1P tumors are indeed more basal than the KP control tumors [12]. This raises the question if not only BRCA1-deficient breast tumors but also sporadic basal-like tumors would be dependent on EZH2 overexpression. Our observation that restoration of BRCA1 function negates the sensitivity of tumor cells to DZNep would argue against this. However, although BRCA1 mutations in sporadic cancer are rare, there are indications that a significant proportion of sporadic breast tumors share traits with BRCA1-deficient tumors, a feature termed BRCAness [41]. Alterations in genes functioning in the same biochemical pathways as BRCA1 could effectively result in loss of BRCA1 function [9]. Sporadic basal-like tumors that exhibit this feature may be specifically sensitive to EZH2 inhibition. Recently, Gonzalez and colleagues [42] showed that knock-down of EZH2 reduced the proliferation of two ER-negative human breast cancer cell lines. Intriguingly, this effect seemed partly due to an upregulation of BRCA1 protein levels. This is in disagreement with our data which show that cells without BRCA1 are particularly sensitive to EZH2 reduction, suggesting that repression of Brca1 is not the main oncogenic function of EZH2. Moreover, breast tumors in BRCA1-mutation carriers show invariably loss of the other BRCA1 allele, indicating that selection for loss of BRCA1 expression is not achieved by high levels of EZH2. However, the observation that these two basal-like breast cancer cell lines are also sensitive to EZH2 inhibition, and the repeated observation that EZH2 overexpression characterizes basal-like breast tumors, warrants the further investigation of EZH2 as a druggable target.
###end p 67
###begin p 68
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EZH2 </italic>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 642 650 642 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Unfortunately, our preliminary in vivo studies with DZNep revealed substantial toxicity in mice (data not shown). We are currently investigating whether this is due to a dependence of certain normal cell types on EZH2 expression, or whether this is due to chemical properties of DZNep. The former would complicate EZH2 inhibition as therapeutic strategy in breast cancer, whereas the latter may be resolved by using other EZH2 inhibitors or DZNep-analogs, which are currently being developed. In addition, although DZNep inhibits sphere-formation of BRCA1-deficient tumor cells and considering the role of EZH2 in stem cells and cancer [43], in vivo studies will be required to determine whether targeting of EZH2 by itself or in combination with other treatments can result in complete eradication of the tumor.
###end p 68
###begin title 69
Conclusions
###end title 69
###begin p 70
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
The preclinical studies and clinical trials with combinations of platinum drugs and Poly(ADP-ribose) polymerase (PARP) inhibitors against BRCA1-mutated breast cancers constitute one example of how insight into the genetic make-up of a tumor subtype can provide a targeted and possibly more effective treatment [34,44]. Our data show that BRCA1-deficient tumor cells are selectively dependent on EZH2 expression, and suggest that pharmacological disruption of EZH2 could provide another individualized approach for the treatment of BRCA1-mutated breast cancers, and possibly also for sporadic basal-like breast tumors.
###end p 70
###begin title 71
Abbreviations
###end title 71
###begin p 72
###xml 444 456 444 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 456 457 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 456 459 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 463 464 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 465 466 465 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 463 466 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 562 574 562 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K14cre;Brca1</italic>
###xml 574 575 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 576 577 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 578 579 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 580 581 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 574 581 574 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>w</italic>.<italic>t</italic>/<italic>w</italic>.<italic>t</italic></sup>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">;p53</italic>
###xml 585 586 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 587 588 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 585 588 585 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic>/<italic>F</italic></sup>
###xml 72 78 <span type="species:ncbi:9913">bovine</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
###xml 261 271 <span type="species:ncbi:7227">Drosophila</span>
###xml 307 311 <span type="species:ncbi:9913">calf</span>
###xml 324 329 <span type="species:ncbi:9606">human</span>
###xml 369 380 <span type="species:ncbi:3704">horseradish</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
BAC: bacterial artificial chromosome; BRCA1: breast cancer 1 gene; BSA: bovine serum albumin; DAB: diaminobenzidine; DMEM: Dulbecco's Modified Eagle Medium; DMSO: dimethyl sulfoxide; DZNep: 3-deazaneplanocin A; ER: estrogen receptor; EZH2: human homolog of the Drosophila enhancer of zeste gene; FCS: fetal calf serum; HER: human epidermal growth factor receptor; HRP: horseradish peroxidase; IC50: half maximal inhibitory concentration; KB1P: K14cre;Brca1F/F;p53F/F, cells derived from mammary tumors arising in mice with this genotype are BRCA1-deficient; KP: K14cre;Brca1w.t/w.t;p53F/F, cells derived from mammary tumors arising in mice with this genotype are BRCA1-proficient; PARP: Poly(ADP-ribose) polymerase; PBS: phosphate-buffered saline; PcG: Polycomb Group; PR: progesterone receptor; PRC2: Polycomb Repressive Complex 2; RT-PCR: reverse-transcription polymerase chain reaction; SCM: stem cell medium; siRNA: small interfering RNA; TSA: trichostatin A.
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The authors declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
###xml 364 367 364 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 438 443 <span type="species:ncbi:9606">human</span>
AP initiated the study, conceived the design with MvL and JJ, and wrote the manuscript with JP. JP participated in the design and performed most of the experiments and data analysis. RD performed the experiments with the reconstituted cell lines she created. XL provided the panel of cell lines and micro-array data. BE advised on the set-up and analysis of the IC50 studies. PC performed western blots and quantitative PCRs. PN provided human tumor samples. SA participated in the immunohistochemical analysis of those samples. QY provided the DZNep. MvL and JJ gave expert advice throughout the study. All authors read and approved the final manuscript.
###end p 76
###begin title 77
Supplementary Material
###end title 77
###begin title 78
Additional file 1
###end title 78
###begin p 79
A PDF file containing a figure that shows that DZNep prevents sphere-formation in three independent BRCA1-deficient cell lines. Phase contrast images are shown of KB1P-3.12, 30.3 and 40.1 cells three days after plating in serum-free medium with defined growth factors on ultra-low binding plates in the presence of 5 muM 3-deazaneplanocin A (DZNep) or dimethyl sulfoxide (DMSO).
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Acknowledgements
###end title 81
###begin p 82
###xml 240 248 240 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 240 247 <span type="species:ncbi:562">E. coli</span>
The authors acknowledge Anke Sparmann and Mathijs Voorhoeve for critical reading of the manuscript and Joep Vissers for helpful discussions. We thank Haydn Prosser for providing the pgk/EM7 Neo/KanR-positive selection cassette (pCEI1). The E. coli SW102 strain was a gift from Neal Copeland and Nancy Jenkins. We thank Peter Bouwman and Hanneke van der Gulden for providing the modified RP11-812O5 BAC. Funding of the authors was as follows: JP (Roland-Ernst Foundation scholarship), RD, XL, BE and JJ (Dutch Cancer Society, NKI 2007-3772), SA (Dutch Cancer Society, NKI 2007-3749), PC, AP and MvL (Dutch Cancer Society, NKI 2007-3803 and Centre for Biomedical Genetics), PN (NKI/AvL) and QY (A*STAR). None of the funding bodies had any say in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
###end p 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 83
###begin article-title 84
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 84
###begin article-title 85
Treating the genetic make-up of breast cancer: a new fashion?
###end article-title 85
###begin article-title 86
HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer
###end article-title 86
###begin article-title 87
The CD44+/CD24- phenotype is enriched in basal-like breast tumors
###end article-title 87
###begin article-title 88
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer
###end article-title 88
###begin article-title 89
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer
###end article-title 89
###begin article-title 90
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution
###end article-title 90
###begin article-title 91
Basal-like breast cancer and the BRCA1 phenotype
###end article-title 91
###begin article-title 92
Brca1 controls homology-directed DNA repair
###end article-title 92
###begin article-title 93
###xml 16 21 <span type="species:ncbi:9606">human</span>
BRCA1 regulates human mammary stem/progenitor cell fate
###end article-title 93
###begin article-title 94
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer
###end article-title 94
###begin article-title 95
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
###end article-title 95
###begin article-title 96
Stem cell regulation by polycomb repressors: postponing commitment
###end article-title 96
###begin article-title 97
Polycomb silencers control cell fate, development and cancer
###end article-title 97
###begin article-title 98
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
###end article-title 98
###begin article-title 99
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
###end article-title 99
###begin article-title 100
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
###end article-title 100
###begin article-title 101
###xml 86 91 <span type="species:ncbi:9606">human</span>
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene
###end article-title 101
###begin article-title 102
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
###end article-title 102
###begin article-title 103
Role of histone H3 lysine 27 methylation in Polycomb-group silencing
###end article-title 103
###begin article-title 104
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
###end article-title 104
###begin article-title 105
Further evidence for BRCA1 communication with the inactive X chromosome
###end article-title 105
###begin article-title 106
###xml 4 12 <span type="species:ncbi:9606">Children</span>
The Children's Hospital and Research Center
###end article-title 106
###begin article-title 107
Mosaic complementation demonstrates a regulatory role for myosin VIIa in actin dynamics of stereocilia
###end article-title 107
###begin article-title 108
Simple and highly efficient BAC recombineering using galK selection
###end article-title 108
###begin article-title 109
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice
###end article-title 109
###begin article-title 110
Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors
###end article-title 110
###begin article-title 111
The properties of a mammary gland cancer stem cell
###end article-title 111
###begin article-title 112
The molecular portraits of breast tumors are conserved across microarray platforms
###end article-title 112
###begin article-title 113
A gene-expression signature as a predictor of survival in breast cancer
###end article-title 113
###begin article-title 114
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype
###end article-title 114
###begin article-title 115
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
###end article-title 115
###begin article-title 116
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
###end article-title 116
###begin article-title 117
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells
###end article-title 117
###begin article-title 118
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
The polycomb-group gene Ezh2 is required for early mouse development
###end article-title 118
###begin article-title 119
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
###end article-title 119
###begin article-title 120
###xml 51 56 <span type="species:ncbi:9606">human</span>
Control of developmental regulators by Polycomb in human embryonic stem cells
###end article-title 120
###begin article-title 121
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells
###end article-title 121
###begin article-title 122
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
###end article-title 122
###begin article-title 123
Hallmarks of 'BRCAness' in sporadic cancers
###end article-title 123
###begin article-title 124
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
###end article-title 124
###begin article-title 125
###xml 90 95 <span type="species:ncbi:9606">human</span>
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
###end article-title 125
###begin article-title 126
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
###end article-title 126
###begin article-title 127
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 127

